keyword
https://read.qxmd.com/read/38597939/inhibition-of-notch3-hey1-ameliorates-peribiliary-hypoxia-by-preventing-hypertrophic-hepatic-arteriopathy-in-biliary-atresia-progression
#21
JOURNAL ARTICLE
Xiaopan Chang, Shuiqing Chi, Xi Zhang, Xiangyang Li, Cheng Yu, Ying Zhou, Shaotao Tang
Emerging evidence indicates the presence of vascular abnormalities and ischemia in biliary atresia (BA), although specific mechanisms remain undefined. This study examined both human and experimental BA. Structural and hemodynamic features of hepatic arteries were investigated by Doppler ultrasound, indocyanine green angiography, microscopic histology, and invasive arterial pressure measurement. Opal multiplex immunohistochemistry, western blot, and RT-PCR were applied to assess Notch3 expression and the phenotype of hepatic arterial smooth muscle cells (HASMCs)...
April 10, 2024: Histochemistry and Cell Biology
https://read.qxmd.com/read/38595869/early-diagnosis-of-cardiovascular-diseases-in-the-era-of-artificial-intelligence-an-in-depth-review
#22
REVIEW
Naiela E Almansouri, Mishael Awe, Selvambigay Rajavelu, Kudapa Jahnavi, Rohan Shastry, Ali Hasan, Hadi Hasan, Mohit Lakkimsetti, Reem Khalid AlAbbasi, Brian Criollo Gutiérrez, Ali Haider
Cardiovascular diseases (CVDs) are significant health issues that result in high death rates globally. Early detection of cardiovascular events may lower the occurrence of acute myocardial infarction and reduce death rates in people with CVDs. Traditional data analysis is inadequate for managing multidimensional data related to the risk prediction of CVDs, heart attacks, medical image interpretations, therapeutic decision-making, and disease prognosis due to the complex pathological mechanisms and multiple factors involved...
March 2024: Curēus
https://read.qxmd.com/read/38594610/focal-ischemic-myocardial-fibrosis-assessed-by-late-gadolinium-enhancement-cardiovascular-magnetic-resonance-in-patients-with-hypertrophic-cardiomyopathy
#23
JOURNAL ARTICLE
Yang Zhi, Fu-Dan Gui, Meng Xue, Yi-Tian Long, Wen Miao, You Yi, Liang-Chao Gao, Fu Bing, Shu-Yue Pan
BACKGROUND: In patients with hypertrophic cardiomyopathy (HCM), ischemic myocardial fibrosis assessed by late gadolinium enhancement (I-LGE) using cardiovascular magnetic resonance (CMR) have been reported. However, the clinical significance of I-LGE has not been completely understood. We aim to evaluate the I-LGE differ phenotypically from HCM without LGE or nonischemic myocardial fibrosis assessed by late gadolinium enhancement (NI-LGE) in the left ventricle (LV). METHODS: The patients with HCM whom was underwent CMR were enrolled, using cine cardiac magnetic resonance to evaluate LV function and LGE to detect the myocardial fibrosis...
April 9, 2024: BMC Cardiovascular Disorders
https://read.qxmd.com/read/38593678/multiple-coronary-heart-diseases-are-risk-factors-for-mental-health-disorders-a-mendelian-randomization-study
#24
JOURNAL ARTICLE
Tianwei Meng, Zhiping Liu, Jiawen Liu, Xiaobing Zhang, Chengjia Li, Jiarui Li, Boyu Wang, Yinxiong He, Zengguang Fan, Shilong Xin, Jia Chen, Rui Qie
BACKGROUND: Previous observational studies have suggested associations between Coronary Heart Disease (CHD) and Mental Health Disorders (MHD). However, the causal nature of these relationships has remained elusive. OBJECTIVE: The purpose of this study is to elucidate the causal relationships between eight distinct types of CHD and six types of MHD using Mendelian randomization (MR) analysis. METHODS: The MR analysis employed a suite of methods including inverse variance-weighted (IVW), MR-Egger, weighted mode, weighted median, and simple mode techniques...
April 8, 2024: Heart & Lung: the Journal of Critical Care
https://read.qxmd.com/read/38592289/short-and-mid-term-outcomes-of-early-alcohol-septal-ablation-therapy-for-patients-with-mildly-symptomatic-hypertrophic-obstructive-cardiomyopathy-a-tertiary-center-experience
#25
JOURNAL ARTICLE
Veysel Oktay, Sukru Arslan, Muhammed Heja Gecit, Zubeyir Bulat, Mehmet Emin Gokce
Background: Left ventricular outflow tract obstruction (LVOTO) impairs survival and diminishes quality of life in patients with hypertrophic obstructive cardiomyopathy (HOCM). In this study, we aimed to investigate the safety and the efficacy of earlier alcohol septal ablation (ASA) in patients with HOCM. Methods: A total of 47 patients with mildly symptomatic HOCM (NYHA II) and having poor functional capacity despite maximal tolerated medical therapy were included. Results: The mean age of the patients was 55 ± 14, and 57% of the patients were male...
March 1, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38591260/long-term-safety-and-efficacy-of-mavacamten-in-symptomatic-obstructive-hypertrophic-cardiomyopathy-interim-results-of-the-pioneer-ole-study
#26
JOURNAL ARTICLE
Ahmad Masri, Steven J Lester, John C Stendahl, Sheila M Hegde, Amy J Sehnert, Ganesh Balaratnam, Ashish Shah, Shawna Fox, Andrew Wang
BACKGROUND: The phase 2 PIONEER-HCM (Phase 2 Open-label Pilot Study Evaluating Mavacamten in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction) study showed that mavacamten improved left ventricular outflow tract gradients, exercise capacity, and symptoms in patients with obstructive hypertrophic cardiomyopathy (HCM), but the results of longer-term treatment are less well described. We report interim results from the PIONEER-OLE (PIONEER Open-Label Extension) study, the longest-term study of mavacamten in patients with symptomatic obstructive HCM...
April 9, 2024: Journal of the American Heart Association
https://read.qxmd.com/read/38590469/fever-unveiling-a-hidden-cardiac-condition-a-case-of-pediatric-hypertrophic-obstructive-cardiomyopathy
#27
Sneha Reddy, Ashish Varma, Amar Taksande
This case report presents the clinical management of a 18-month-old female child who presented with fever, cough, and cold symptoms for eight days. Despite initial treatment with antipyretic syrup, the persistence of symptoms prompted further evaluation, revealing signs of hypertrophic obstructive cardiomyopathy (HOCM) on echocardiography. The patient was subsequently initiated on beta-blocker therapy and supportive care, leading to clinical improvement and eventual discharge. This case underscores the importance of considering cardiac etiologies in pediatric patients presenting with nonspecific symptoms...
March 2024: Curēus
https://read.qxmd.com/read/38590299/understanding-wound-healing-in-obesity
#28
REVIEW
Asha Cotterell, Michelle Griffin, Mauricio A Downer, Jennifer B Parker, Derrick Wan, Michael T Longaker
Obesity has become more prevalent in the global population. It is associated with the development of several diseases including diabetes mellitus, coronary heart disease, and metabolic syndrome. There are a multitude of factors impacted by obesity that may contribute to poor wound healing outcomes. With millions worldwide classified as obese, it is imperative to understand wound healing in these patients. Despite advances in the understanding of wound healing in both healthy and diabetic populations, much is unknown about wound healing in obese patients...
March 20, 2024: World Journal of Experimental Medicine
https://read.qxmd.com/read/38590297/a-case-report-of-percutaneous-intramyocardial-septal-radiofrequency-ablation-in-an-adult-with-re-obstruction-after-morrow-procedure
#29
Huiyi Wang, Changhui Lei, Liwen Liu
BACKGROUND: Some patients with hypertrophic cardiomyopathy (HCM) re-occur with drug-refractory symptoms but are not eligible for re-operation after the Morrow procedure. Traditional treatment options are limited. We present the first case of the use of ultrasound-guided percutaneous intramyocardial septal radiofrequency ablation (PIMSRA) for the treatment of a patient with HCM combined with congenital anatomically corrected malposition of the great arteries (MGA) after Morrow procedure...
April 2024: European Heart Journal. Case Reports
https://read.qxmd.com/read/38589351/author-correction-individualized-interactomes-for-network-based-precision-medicine-in-hypertrophic-cardiomyopathy-with-implications-for-other-clinical-pathophenotypes
#30
Bradley A Maron, Rui-Sheng Wang, Sergei Shevtsov, Stavros G Drakos, Elena Arons, Omar Wever-Pinzon, Gordon S Huggins, Andriy O Samokhin, William M Oldham, Yasmine Aguib, Magdi H Yacoub, Ethan J Rowin, Barry J Maron, Martin S Maron, Joseph Loscalzo
No abstract text is available yet for this article.
April 8, 2024: Nature Communications
https://read.qxmd.com/read/38589224/machine-learning-based-detection-of-sleep-disordered-breathing-in-hypertrophic-cardiomyopathy
#31
JOURNAL ARTICLE
Keitaro Akita, Shigetaka Kageyama, Sayumi Suzuki, Kazuto Ohno, Masamitsu Kamakura, Ryuzo Nawada, Chiei Takanaka, Yasushi Wakabayashi, Takahiro Kanda, Kei Tawarahara, Masahiro Mutoh, Masaki Matsunaga, Satoru Suwa, Yasuyo Takeuchi, Hiroki Sakamoto, Hideki Saito, Kazusa Hayashi, Nobuyuki Wakahara, Kyoko Unno, Takenori Ikoma, Ryota Sato, Keisuke Iguchi, Terumori Satoh, Makoto Sano, Kenichiro Suwa, Yoshihisa Naruse, Hayato Ohtani, Masao Saotome, Yuichiro Maekawa
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is often concomitant with sleep-disordered breathing (SDB), which can cause adverse cardiovascular events. Although an appropriate approach to SDB prevents cardiac remodelling, detection of concomitant SDB in patients with HCM remains suboptimal. Thus, we aimed to develop a machine learning-based discriminant model for SDB in HCM. METHODS: In the present multicentre study, we consecutively registered patients with HCM and performed nocturnal oximetry...
April 8, 2024: Heart
https://read.qxmd.com/read/38588067/accurate-diagnosis-of-apical-hypertrophic-cardiomyopathy-using-explainable-advanced-ecg-analysis
#32
JOURNAL ARTICLE
Rebecca K Hughes, George D Thornton, James W Malcolmson, Iain Pierce, Shafik Khoury, Amanda Hornell, Kristopher Knott, Gabriella Captur, James C Moon, Todd T Schlegel, Martin Ugander
BACKGROUND AND AIMS: Typical electrocardiogram (ECG) features of apical hypertrophic cardiomyopathy (ApHCM) include tall R waves and deep or giant T-wave inversion in the precordial leads, but these features are not always present. The ECG is used as the gatekeeper to cardiac imaging for diagnosis. We tested whether explainable advanced ECG (A-ECG) could accurately diagnose ApHCM. METHODS: A-ECG analysis was performed on standard resting 12-lead ECGs in patients with ApHCM (n = 75 overt, n = 32 relative [<15mm hypertrophy]), a subgroup of which underwent cardiovascular magnetic resonance, n = 92), and comparator subjects (n = 2449), including healthy volunteers (n = 1672), patients with coronary artery disease (n = 372), left ventricular electrical remodelling (n = 108), ischemic (n = 114) or non-ischemic cardiomyopathy (n = 57), and asymmetrical septal hypertrophy (ASH) HCM (n = 126)...
April 8, 2024: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://read.qxmd.com/read/38586909/betamethasone-transdermal-administration-combined-with-fractional-er-yag-lasers-or-microplasma-radiofrequency-technology-improved-hypertrophic-scars-a-retrospective-study
#33
JOURNAL ARTICLE
Liu Liu, Huizheng Li, Wen Zhang, Mo Cao, Lisha Yu, Xingjian Cheng
OBJECTIVE: This retrospective study aims to compare the efficacy rates in treating hypertrophic scars among four distinct groups of patients who either underwent fractional Erbium: yttrium-aluminum-garnet (Er:YAG) laser or microplasma radiofrequency technology as standalone treatments or in combination with compound betamethasone transdermal administration. METHOD: The study retrospectively examined 208 patients treated at our institution from April 2011 to December 2022 for hypertrophic scars, receiving no less than three treatments (with an interval of 8 weeks between each)...
April 8, 2024: Journal of Cosmetic Dermatology
https://read.qxmd.com/read/38586026/the-24-hour-time-course-of-integrated-molecular-responses-to-resistance-exercise-in-human-skeletal-muscle-implicates-myc-as-a-hypertrophic-regulator-that-is-sufficient-for-growth
#34
Sebastian Edman, Ronald G Jones, Paulo R Jannig, Rodrigo Fernandez-Gonzalo, Jessica Norrbom, Nicholas T Thomas, Sabin Khadgi, Pieter Jan Koopmans, Francielly Morena, Calvin S Peterson, Logan N Scott, Nicholas P Greene, Vandre C Figueiredo, Christopher S Fry, Liu Zhengye, Johanna T Lanner, Yuan Wen, Björn Alkner, Kevin A Murach, Ferdinand von Walden
Molecular control of recovery after exercise in muscle is temporally dynamic. A time course of biopsies around resistance exercise (RE) combined with -omics is necessary to better comprehend the molecular contributions of skeletal muscle adaptation in humans. Vastus lateralis biopsies before and 30 minutes, 3-, 8-, and 24-hours after acute RE were collected. A time-point matched biopsy-only group was also included. RNA-sequencing defined the transcriptome while DNA methylomics and computational approaches complemented these data...
March 27, 2024: bioRxiv
https://read.qxmd.com/read/38585341/acne-induced-pathological-scars-pathophysiology-and-current-treatments
#35
REVIEW
Wanyu Xu, Dorsa Gholamali Sinaki, Yuchen Tang, Yunsheng Chen, Yixin Zhang, Zheng Zhang
Acne is a common chronic inflammatory dermatosis that can lead to pathological scars (PSs, divided into hypertrophic scars and keloids). These kinds of abnormal scars seriously reduce the quality of life of patients. However, their mechanism is still unclear, resulting in difficult clinical prevention, unstable treatment effects and a high risk of recurrence. Available evidence supports inflammatory changes caused by infection as one of the keys to abnormal proliferation of skin fibroblasts. In acne-induced PSs, increasing knowledge of the immunopathology indicates that inflammatory cells directly secrete growth factors to activate fibroblasts and release pro-inflammatory factors to promote the formation of PSs...
2024: Burns and Trauma
https://read.qxmd.com/read/38585254/updated-evaluation-of-agalsidase-alfa-enzyme-replacement-therapy-for-patients-with-fabry-disease-insights-from-real-world-data
#36
REVIEW
Sandro Feriozzi, Cristina Chimenti, Ricardo Claudio Reisin
The clinical use of agalsidase alfa as enzyme replacement therapy (ERT) for Fabry disease (FD) has spread since 2001, and a large body of evidence of its effectiveness has been collected. This review presents the clinical and laboratory results achieved with agalsidase alfa, which has been published in the literature. Agalsidase alfa infusion slows down or stops the progression of renal damage, expressed by reduction or stabilization of the annual decline of the glomerular filtration rate; yearly decrease of glomerular filtration rate (slope) sometimes is reduced until its stabilization...
2024: Drug Design, Development and Therapy
https://read.qxmd.com/read/38584969/cd44-expression-in-renal-tubular-epithelial-cells-in-the-kidneys-of-rats-with-cyclosporine-induced-chronic-kidney-disease
#37
JOURNAL ARTICLE
Kohei Matsushita, Takeshi Toyoda, Hirotoshi Akane, Tomomi Morikawa, Kumiko Ogawa
Renal tubular epithelial cell (TEC) injury is the most common cause of drug-induced kidney injury (DIKI). Although TEC regeneration facilitates renal function and structural recovery following DIKI, maladaptive repair of TECs leads to irreversible fibrosis, resulting in chronic kidney disease (CKD). CD44 is specifically expressed in TECs during maladaptive repair in several types of rat CKD models. In this study, we investigated CD44 expression and its role in renal fibrogenesis in a cyclosporine (CyA) rat model of CKD...
April 2024: Journal of Toxicologic Pathology
https://read.qxmd.com/read/38584800/correction-to-diagnostic-and-prognostic-electrocardiographic-features-in-patients-with-hypertrophic-cardiomyopathy
#38
COMMENT
(no author information available yet)
[This corrects the article DOI: 10.1093/eurheartjsupp/suad074.].
May 2023: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://read.qxmd.com/read/38584533/mavacamten-a-review-of-a-novel-therapeutic-approach-for-hypertrophic-cardiomyopathy
#39
JOURNAL ARTICLE
Ayesha Abdul Qadir Memon, Areeba Shamim, Sanoober Mirza, Muhammad Osama, Iyad Naeem Muhammad, Calvin R Wei
Hypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that Mavacamten can reduce Left Ventricular Outflow Tract (LVOT) involvement, cardiac hypercontraction, and hypertrophy...
April 5, 2024: Cardiovascular & Hematological Agents in Medicinal Chemistry
https://read.qxmd.com/read/38582690/corrigendum-to-plasma-growth-differentiation-factors-8-and-11-levels-in-cats-with-congestive-heart-failure-secondary-to-hypertrophic-cardiomyopathy-j-vet-cardiol-25-2019-oct-41-51
#40
V K Yang, J E Rush, S Bhasin, A J Wagers, R T Lee
No abstract text is available yet for this article.
March 28, 2024: Journal of Veterinary Cardiology: the Official Journal of the European Society of Veterinary Cardiology
keyword
keyword
70453
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.